News & Events
-
September 17, 2018
Critical Path Institute and SIGNATOPE GmbH Team Up to Advance Research on Biomarkers for Drug-induced Organ Injuries
TUCSON, Ariz. and REUTLINGEN, September 17, 2018 — Critical Path Institute’s Predictive Safety Testing Consortium (PSTC) and SIGNATOPE GmbH are excited to announce a new project, joining efforts on analyzing and qualifying promising protein safety biomarkers in mouse, rat, dog, monkey, and human. The work is expected to increase understanding of drug-induced toxicities... -
September 6, 2018
Doris Duke Charitable Foundation Awards Grant to Critical Path Institute to Advance Therapies for Sickle Cell Disease
Contacts: Kissy Black, Critical Path Institute [email protected], 615.298.1144 Kristin Roth-Schrefer, Communications Director [email protected], 212.974.7003 Nina Chung, Communications Associate [email protected], 212.974.7006 Critical Path Institute (C-Path) Will Plan a Consortium of Stakeholders Focused on Developing Therapies for Sickle Cell Disease NEW YORK, September 6, 2018 — In a continuing effort to spur advancements in treating... -
September 1, 2018
Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis
Rancoita PMV, Cugnata F, Gibertoni Cruz AL, Borroni E, Hoosdally SJ, Walker TM, et al. Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018 Sep;62(9).
-
August 10, 2018
CPAD’s Has Two Posters Accepted to Alzheimer’s Association International Conference
The Alzheimer’s Association International Conference (AAIC) is the largest annual scientific meeting with focus on Alzheimer disease (AD). More than 6,500 researchers and participants from pharma, academia, patent-advocacy organizations and other groups came together in Chicago between July 22nd and 26th to exchange the latest developments and research results. Each year, on behalf of our... -
August 10, 2018
Evidence-Based Treatment Decisions In Transplantation: The Right Dose & Regimen for the Right Patient/Individualized Treatment
The following originally appeared on fda.gov: Summary: The Food and Drug Administration is announcing the following public workshop titled “Evidence-Based Treatment Decisions In Transplantation: The Right Dose & Regimen for the Right Patient/Individualized Treatment. This public workshop is planned and presented in collaboration with the Transplant Therapeutics Consortium (TTC), a public-private partnership between the FDA, transplantation...